4HF Biotec GmbH

4HF Biotec GmbH is working on innovative therapies to treat cancer. The company uses cancer data, computer science and AI-based drug discovery to identify and develop novel cancer-specific targets and associated small molecule effectors to develop potent anti-cancer drugs with increased precision in targeting tumor cells. These drugs are designed to increase efficacy and reduce side effects, ultimately improving patient outcomes. One of the company’s pioneering projects aims to improve the delivery of chemotherapeutics to cancer cells by utilizing the innovative concept of small molecule drug conjugates, which combine the precision of targeted therapy with highly potent toxins. These anti-cancer drugs deliver effective chemotherapeutic agents directly to cancer cells while sparing healthy tissue. Among the various technologies, 4HF has chosen to use small molecules to create a new class of small molecule drug conjugates (SMDCs) that offer significant advantages such as high penetration into cells and tissues, high stability and low immunogenicity. This approach can lead to improved pharmacokinetics and reduced toxicity. Their research ultimately focuses on the development of therapies for various types of cancer, with a specialized focus on solid tumors that are currently difficult to treat with conventional treatments.